# Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

> **NCT07286214** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Sanofi** · enrollment: 300 (estimated)

## Conditions studied

- Polymyalgia Rheumatica

## Interventions

- **DRUG:** Sarilumab
- **DRUG:** Sarilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07286214
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2029-06-04
- **Final completion:** 2029-07-16
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07286214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07286214, "Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07286214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*